ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $264,960.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 3,312 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.00, for a total value of $264,960.00. Following the completion of the sale, the chief financial officer directly owned 180,393 shares of the company’s stock, valued at $14,431,440. The trade was a 1.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Up 1.3%

Shares of ANI Pharmaceuticals stock traded up $1.07 during trading hours on Tuesday, hitting $81.20. 271,945 shares of the company’s stock traded hands, compared to its average volume of 399,089. The stock has a 50 day simple moving average of $79.18 and a 200-day simple moving average of $79.36. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a market cap of $1.85 billion, a PE ratio of 20.56 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a twelve month low of $61.17 and a twelve month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s revenue was up 20.5% on a year-over-year basis. During the same period last year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ANIP shares. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, June 1st. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $107.33.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ANIP. Divisadero Street Capital Management LP acquired a new position in ANI Pharmaceuticals in the third quarter valued at approximately $21,454,000. Apis Capital Advisors LLC boosted its stake in ANI Pharmaceuticals by 28.1% in the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock valued at $15,022,000 after acquiring an additional 36,000 shares during the period. Oliver Luxxe Assets LLC bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $1,823,000. Vanguard Group Inc. lifted its position in ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the last quarter. Finally, Artemis Investment Management LLP bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $1,706,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.